



COMPANY BACKGROUND

Quality Healthcare That Is Easily Accessible

- Rusan Pharma Ltd. is a fully integrated global pharmaceutical company specializing in the treatment of 'Addiction and Pain Management'.
- Currently, Rusan is one of the few Indian companies that offers a 'One-Stop-Solution' for treating various forms of addictions such as drugs, alcohol and tobacco.
- We are one of the largest suppliers of life saving drugs to various organizations (NACO, UNODC, UNOPS, Global Fund) and ministries of health in various emerging markets.





To bring forward highly innovative and technology driven treatment options for various neglected diseases with the best quality products for our consumers.



Rusan firmly believes that access to quality healthcare is a right, not a privilege. We will endeavour to ensure the availability of world class, quality medicines at affordable prices, across the globe and are committed to work towards a healthier & happier world.



AWARDS & ACCREDITATIONS





MANUFACTURING FACILITY MILESTONES



(S.Africa)
Acquisition by

Rusan Pharma

Pithampur API Inauguration November 2023 Quantys Clinical Pvt Ltd. CRO Centre Inaugurated

NSRT Pvt. Ltd R&D Centre Inaugurated Transdermal Patch Unit [Kandla SEZ (Unit-II)] Inaugurated



OUR CORE SPECIALIZATION

One Stop Solution, Promoted By Innovation

Our mantra to success is hinged on our core strengths of Research & Development, Manufacturing and Marketing of Formulations, APIs and their Intermediates.



Core specialization in De-addiction, Pain Management and Tuberculosis



One of the 6 notified companies in India to import Narcotics



Specialist in Narcotics and Psychotropic drugs



Innovating new delivery system



Backward integration to API





KEY BUSINESS UNITS





OUR BUSINESS




(FDF)



OUR GLOBAL PRESENCE









RUSAN'S FACILITIES

Head Office

- Mumbai (Maharashtra, India)

API Facility I

- Ankleshwar (Gujarat, India)

API Facility II

- Pithampur (Madhya Pradesh, India)

Formulation Facilities

- Kandla SEZ (Unit-I) (Gujarat, India)
- Kandla SEZ (Unit-II) (Patches) (Gujarat, India)
- Dehradun (Uttarakhand, India)

Other Facilities

- Kandla SEZ NSRT (R&D) (Gujarat, India)
- Kandla SEZ Quantys (CRO) (Gujarat, India)



API Facility II (Pithampur)

Formulation Facility I (Kandla Unit I)

Formulation Facility II (Kandla Unit II)

Formulation Facility III (Dehradun)

API Facility I

ANKLESHWAR (GUJARAT, INDIA)



Installed Capacity

Production	Capacity (KL)
Plant – I	13.0KL
Plant – II	15.5KL
Total	28.5 KL (32Tons) of annual production

*Capacity as per 3 shift basis





Approved by

USFDA



EUROPE-BELGIUM



CANADA



STATE-GMP



BRAZIL



FAMHP- Belgium





WHO-CDSCO





API Facility II (Pithampur)

Formulation Facility I (Kandla Unit I)

Formulation Facility II (Kandla Unit II)

Formulation Facility III (Dehradun)

API Facility II

PITHAMPUR (MADHYA PRADESH, INDIA)







Planned

USFDA







WHO (India)

State GMP







API Facility II (Pithampur)

Formulation Facility I (Kandla Unit I)

Formulation Facility II (Kandla Unit II)

Formulation Facility III (Dehradun)

Formulation Facility I

KANDLA UNIT I (GUJARAT, INDIA)



Installed Capacity

Dosage Form	Annual Capacity
Tablet	1800 Million
Capsule	130 Million
Sachet	60 Million
Beta-Lactam Capsule	450 Million
Beta-Lactam Dry Syrup	20 Million
Injectable (Lyo- Vial)	0.4 Million
Injectable (Liquid Vial)	1.8 Million
Ampoule	11 Million
Cream & Ointment	4 Million

^{*}Capacity as per 3 shift basis

Approved by

ANVISA - Brazil So

South Africa

WHO (India)







Tanzania

Zimbabwe

State GMP

UAE-MOH









Planned

EU

Canada

EAEU

PIC/s (Ukraine)









Kenya

Uganda

Mexico









API Facility II (Pithampur)

Formulation Facility I (Kandla Unit I)

Formulation Facility II (Kandla Unit II) Formulation Facility III (Dehradun)

Formulation Facility II

KANDLA UNIT II (GUJARAT, INDIA)



Installed Capacity*

Dosage From	Annual Capacity
Transdermal Patch	6 Million

*Capacity as per 3 shift basis



Approved by

ANVISA - Brazil

TGA

UAE-MOH







State GMP

Uganda



WHO (India)



Planned

EU

Russia







API Facility II (Pithampur)

Formulation Facility I (Kandla Unit I)

Formulation Facility II (Kandla Unit II)

Formulation Facility III (Dehradun)

Formulation Facility III

DEHRADUN (UTTARAKHAND, INDIA)



Installed Capacity

Dosage Form	Annual Capacity
Tablet	2000 Million
Capsule	130 Million
Oral Liquid	11 Million
Transdermal Patch	0.6 Million
Vial	5 Million
Ampoule	72 Million
Prefilled Syringe	6 Million

^{*}Capacity as per 3 shift basis

Approved by

Canada

TGA

ANVISA (Brazil)



EU









UAE-MOH

Tanzania

PIC/S (Ukraine)

WHO (India)

GMP











Planned

UK

Russia

Switzerland







Malaysia

Philippines

Kenya









NAVIN SAXENA RESEARCH & TECHNOLOGY CENTER









NSRT – Integrated approach to Research & Drug Development

CADD

API

FORMULATION DEVELOPMENT

ARD

QA

Approved by

STATE GMP

NSRT - Focus

CNS Drugs

Orphan Drugs

Addiction

Pain Management

Deterrent

Platform

Technologies

- Parkinson's, Alzhimer's, Schizophrenia

- Dengue, Malaria, MDR-Tuberculosis, Zika

- Drugs, Alcohol, Tobacco

- Long-Acting Formulations / Abuse

Improving Efficacy & reducing Side Effects

- New Drug Deliveries using nanotech,

- Needle-free technology

Expertise in handling Narcotic & Psychotropic controlled Substances formulations as per the rules & regulations of India



STATE-OF-THE-ART FACILITY (NSRT)

API





Gram Scale Lab

Kilo Scale Lab

Formulation Development



Lab Scale



Kilo Scale Lab




Nanotechnology Development



STATE-OF-THE-ART FACILITY (NSRT)

CADD





CADD

QC



Gas Chromatography








XRD



Quantys Clinical Pvt. Ltd.









Quantys Clinical - Full spectrum of CRO Services

Independent CRO offering world class services to

Pharmaceutical | Nutraceutical | Biotechnology industries in various stages of drug development

BA / BE studies

Clinical Trials

Bio Analytical Services

QA Services



Service

BRAZIL

Proven expertise in conducting BA/BE studies for patients/clinical trials on various dosage forms viz. oral solid dosages, Suspensions, Depot Injections, Implants, Nasal Spray, Oral Thin Films & Transdermal Patches etc.

Expertise in handling Narcotic & Psychotropic controlled substances formulations as per the rules & regulations of India

> **Approved by WHO**

(INDIA)

GCC

MALAYSIA



Planned

USFDA











STATE-OF-THE-ART FACILITY (QUANTYS)



104 beds 5 independent clinics



LCMS / MS



Ultra Low Temperature Freezers



Pathology Lab



Bioanalytical lab



e-CRF based paperless process

